Evaluation of Hepatitis C virus Infection Analysis in Buddhasothorn hospital by Anti-HCV, HCV Duo with HCV RNA
Article Sidebar
Main Article Content
Abstract
Background: Hepatitis C infection is an important public health problem. Quick diagnosis and cheap price is necessary. The purpose of this study was to evaluate of Hepatitis C diagnostic test results with rapid test, HCV Duo and HCV RNA Viral Load. Aim to use HCV core antigen as an alternative to HCV RNA Viral Load for diagnosis new infections in Buddhasothorn hospital.
Materials and Methods: The samples in this study from patients at Buddhasothorn hospital. 195 cases gave positive result by screened with anti-HCV BiolineTM HCV. All sample were test with Elecsys® HCV Duo, to test anti-HCV and HCV core antigen on the Cobas e801. The result from Elecsys® HCV Duo were compared with HCV RNA by using Xpert® HCV Viral Load reagent on the Cepheid GeneXpert machine.
Results: comparing the results of the HCV core antigen with the HCV RNA Viral Load, it was found Sensitivity 73.74%, specificity 91.67%, positive predictive value 90.12% and negative predictive value 77.19%. The Area Under the Receiver Operating Characteristics (AUROC) showed that test performance between the HCV core antigen and HCV RNA it shown 0.84
Conclusions: HCV core antigen showed good accuracy and precision relate to HCV Viral Load. Therefore, HCV core antigen is a valid and reliable method for confirmation of hepatitis C virus for new infections, by confirm with HCV RNA Viral Load only in case of HCV Duo gave positive for anti-HCV but negative for HCV core antigen or high-risk group of patients. This could reduce the cost of HCV RNA Viral Load up to 40% and helps patients get treatment quickly. To help the Department of Disease Control achieve objectives for Hepatitis C elimination by 2030.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
กรมควบคุมโรค. แนวทางการกำจัดโรคไวรัสตับอักเสบ ซี ประเทศไทยThailand Practice Guideline for Eliminate Hepatitis C. กรุงเทพฯ: เจ. เอส. การพิมพ์; 2563.
Affairs USDoV. Viral Hepatitis and Liver Disease 2018 [Available from: https://www.hepatitis.va.gov/hcv.
Mohamed AA, Elbedewy TA, El-Serafy M, El-Toukhy N, Ahmed W, Ali El Din Z. Hepatitis C virus: A global view. World J Hepatol. 2015;7(26):2676-80.
WHO. Hepatitis C 2023 [Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c#.
Chigbu DI, Loonawat R, Sehgal M, Patel D, Jain P. Hepatitis C Virus Infection: Host⁻Virus Interaction and Mechanisms of Viral Persistence. Cells. 2019;8(4).
Guntipalli P, Pakala R, Kumari Gara S, Ahmed F, Bhatnagar A, Endaya Coronel MK, et al. Worldwide prevalence, genotype distribution and management of hepatitis C. Acta Gastroenterol Belg. 2021;84(4):637-56.
Wasitthankasem R, Wanlapakorn N, Pimsing N, Posuwan N, Poovorawan Y. Simplified Test-to-Treat Strategy for Hepatitis C in Thailand: The Phetchabun Model. The Journal of Infectious Diseases. 2023;228(Supplement_3):S198-S203.
ทรงยศ พิลาสันต์ พร้อมคณะ. โครงการสังเคราะห์ข้อเสนอเชิงนโยบายด้านงบประมาณของการใช้ยาสูตรsofosbuvir/velpatasvir ในการรักษาโรคไวรัสตับอักเสบซีเรื้อรังทุกสายพันธุ์ในประเทศไทย. 2020.
สุลินดา ดามะอู . Evaluation of Hepatitis C Virus Infection Analysis by Anti-HCV and HCV Core Antigen Assays. 2021.
ณัฏฐิยา หิรัญกาญจน์. Prevalence of HCV infection at King Chulalongkorn Memorial Hospital. Chulalongkorn medical journal. 2018.
Zhang K, Wang L, Lin G, Li J. Is Anti-Hepatitis C Virus Antibody Level an Appropriate Marker to Preclude the Need for Supplemental Testing? Intervirology. 2016;58(5):310-7.
กรมควบคุมโรค. แนวทางการดําเนินงานตรวจคัดกรองโรคติดเชื้อไวรัสตับอักเสบบีและซีในประชากรกลุ่มเป้าหมายที่มีความเสี่ยง เพื่อส่งต่อเข้าสู่ระบบการรักษา ในพื้นที่องค์กรปกครองส่วนท้องถิ่น. 2022.
สมาคมโรคตับแห่งประเทศไทย. Thailand Practice Guideline for Eliminate Hepatitis C 2020.
สุดา ลุยศิริโรจนกุล. Hepatitis C: Clinical Importance and Laboratory Diagnosis. Journal of Hematology and Transfusion Medicine. 2009.
Pérez-García A, Aguinaga A, Navascués A, Castilla J, Ezpeleta C. Hepatitis C core antigen: Diagnosis and monitoring of patients infected with hepatitis C virus. International Journal of Infectious Diseases. 2019;89:131-6.
Liver EAftSot. EASL recommendations on treatment of hepatitis C: Final update of the series. Journal of Hepatology. 2020.
Chiquete E, Panduro A. Low Prevalence of Anti-Hepatitis C Virus Antibodies in Mexico: A Systematic Review. Intervirology. 2006;50(1):1-8.
Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. American Journal of Public Health. 1996;86(5):655-61.
Li HC, Lo SY. Hepatitis C virus: Virology, diagnosis and treatment. World J Hepatol. 2015;7(10):1377-89.
Budkowska A. Mechanism of cell infection with hepatitis C virus (HCV)--a new paradigm in virus-cell interaction. Pol J Microbiol. 2009;58(2):93-8.
Preciado MV, Valva P, Escobar-Gutierrez A, Rahal P, Ruiz-Tovar K, Yamasaki L, et al. Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy. World J Gastroenterol. 2014;20(43):15992-6013.
โรงพยาบาลบำรุงราษฎร์. ไวรัสตับอักเสบซี [Available from: https://ww .bumrungrad.com/th/conditions/hepatitis-c.
Blackard JT, Shata MT, Shire NJ, Sherman KE. Acute hepatitis C virus infection: a chronic problem. Hepatology. 2008;47(1):321-31.
Hepatitis C CDC Yellow Book 2024 [Internet]. 2023. Available from: https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/hepatitis-c.
Chuaypen N, Khlaiphuengsin A, Prasoppokakorn T, Susantitaphong P, Prasithsirikul W, Avihingsanon A, et al. Prevalence and genotype distribution of hepatitis C virus within hemodialysis units in Thailand: role of HCV core antigen in the assessment of viremia. BMC Infectious Diseases. 2022;22(1):79.
Hedskog C, Parhy B, Chang S, Zeuzem S, Moreno C, Shafran SD, et al. Identification of 19 Novel Hepatitis C Virus Subtypes-Further Expanding HCV Classification. Open Forum Infect Dis. 2019;6(3):ofz076.
สมาคมโรคตับแห่งประเทศไทย. แนวทางการดูแลรักษาผู้ป่วยไวรัสตับอักเสบซีเรื้อรังในประเทศไทยปีพ.ศ. 2556 (Thailand Practice Guideline for Management of Chronic Hepatitis C 2015). 2015:34-74.
Organization WH. GUIDELINES ON HEPATITIS B AND C TESTING2017.
Couroucé AM, Le Marrec N, Bouchardeau F, Razer A, Maniez M, Laperche S, et al. Efficacy of HCV core antigen detection during the preseroconversion period. Transfusion. 2000;40(10):1198-202.
Modi AA, Liang TJ. Hepatitis C: a clinical review. Oral Dis. 2008;14(1):10-4.
Karoney MJ, Siika AM. Hepatitis C virus (HCV) infection in Africa: a review. Pan Afr Med J. 2013;14:44.
Lo Re V, 3rd, Kostman JR. Management of chronic hepatitis C. Postgrad Med J. 2005;81(956):376-82.
Cobas. Elecsys HCV Duo. 2023.
Majchrzak M, Bronner K, Laperche S, Riester E, Bakker E, Bollhagen R, et al. Multicenter performance evaluation of the Elecsys HCV Duo immunoassay. Journal of Clinical Virology. 2022;156:105293.